Protalix BioTherapeutics (PLX) Assets (2010 - 2026)

Protalix BioTherapeutics has reported Assets for 17 years, with the latest figure at $110.3 million in Q2 2026.

• On a quarterly basis, Assets rose 40.58% year-over-year to $110.3 million in Q2 2026; TTM through Jun 2026 was $110.3 million, a 40.58% increase from a year earlier, with the FY2025 full-year figure at $82.3 million, up 12.16% from the prior year.
• Assets was $110.3 million for Q2 2026 at Protalix BioTherapeutics, up from $102.3 million in the prior quarter.
• The five-year high for Assets was $110.3 million in Q2 2026, with the low at $55.8 million in Q4 2022.
• Average Assets over 5 years is $78.6 million, with a median of $80.4 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Assets plunged 43.96% in 2022, then jumped 54.42% in 2023.
• Over 5 years, Assets stood at $55.8 million in 2022, then jumped by 51.35% to $84.4 million in 2023, then retreated by 13.05% to $73.4 million in 2024, then rose by 12.16% to $82.3 million in 2025, then soared by 33.99% to $110.3 million in 2026.
• The last three Assets figures came in at $110.3 million (Q2 2026), $102.3 million (Q1 2026), and $82.3 million (Q4 2025), per Business Quant data.